Who owns OCULAR THERAPEUTIX, INC?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of OCUL from SEC Form 13F filings across 262 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 262 institutions disclosed 209.0M shares of OCULAR THERAPEUTIX, INC worth $1.60B — about 92.7% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
262
13F holders
$1.60B
value, 2026 filers
92.7%
of shares outstanding (209.0M sh)
40
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of OCUL's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 33.2M | $254.3M | 0.0% | 14.7% | +1.0% |
| 2 | Deep Track Capital, LP | 21.9M | $168.3M | 2.7% | 9.7% | +11.4% |
| 3 | BlackRock, Inc. | 20.0M | $153.2M | 0.0% | 8.9% | +3.1% |
| 4 | Summer Road LLC | 12.5M | $95.6M | 70.7% | 5.5% | +2.1% |
| 5 | Avoro Capital Advisors LLC | 12.4M | $95.0M | 1.0% | 5.5% | -1.3% |
| 6 | Venrock Adviser, LLC | 10.3M | $79.4M | 3.9% | 4.6% | 0.0% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 8.9M | $68.6M | 0.0% | 4% | +1.2% |
| 8 | PRICE T ROWE ASSOCIATES INC /MD/ | 7.2M | $55.1M | 0.0% | 3.2% | -5.7% |
| 9 | Logos Global Management LP | 6.0M | $46.0M | 2.5% | 2.7% | +13.2% |
| 10 | STATE STREET CORP | 5.6M | $42.8M | 0.0% | 2.5% | +6.5% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 5.3M | $40.5M | 0.0% | 2.3% | +5.0% |
| 12 | DIMENSIONAL FUND ADVISORS LP | 3.0M | $22.7M | 0.0% | 1.3% | +6.4% |
| 13 | MARSHALL WACE, LLP | 2.7M | $20.8M | 0.0% | 1.2% | +2047.2% |
| 14 | DELTEC ASSET MANAGEMENT LLC | 2.6M | $20.1M | 3.1% | 1.2% | +6.0% |
| 15 | TWO SIGMA INVESTMENTS, LP | 2.4M | $18.6M | 0.0% | 1.1% | +98.9% |
| 16 | Defilade Capital Management, L.P. | 2.3M | $17.5M | 2.9% | 1% | +52.7% |
| 17 | Balyasny Asset Management L.P. | 2.2M | $16.6M | 0.0% | 1% | -5.0% |
| 18 | UBS Group AG | 2.1M | $16.3M | 0.0% | 0.9% | +37.0% |
| 19 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.0M | $15.0M | 0.0% | 0.9% | -1.0% |
| 20 | NORTHERN TRUST CORP | 1.9M | $14.3M | 0.0% | 0.8% | +3.3% |
| 21 | Invesco Ltd. | 1.8M | $14.1M | 0.0% | 0.8% | +37.2% |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.7M | $13.2M | 0.0% | 0.8% | +12.2% |
| 23 | Woodline Partners LP | 1.7M | $12.8M | 0.0% | 0.7% | 0.0% |
| 24 | GOLDMAN SACHS GROUP INC | 1.5M | $11.8M | 0.0% | 0.7% | -12.4% |
| 25 | Nuveen, LLC | 1.4M | $10.9M | 0.0% | 0.6% | -16.1% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.